Abstract：【Objective】To explore the stimulator of interferon genes (STING) signaling in the development and prognosis of gastric cancer.【Methods】A total of 210 patients with gastric cancer who underwent surgical resection in our hospital were selected for the study. Immunohistochemistry was used to detect the STING expression in gastric cancer tissue and adjacent tissues of surgical resection. The follow-up data of patients were included. Then Kaplan-Meier and Log-rank tests were applied for analyzing the relationships between the prognosis and STING expression. Cox regression model was used to analyze the influencing factors of tumor-free survival time as well. 【Results】The positive rate of STING in gastric cancer tissues was higher than that in adjacent tissues (P<0.05). According to TNM staging, among those 210 patients, 55 cases were categorized in stage Ⅰ, 33 cases were in stage Ⅱ, 122 cases were in stage Ⅲ. Follow-up was completed in 195 patients accounting for 92.9% (195/210). Only 15 cases were lost to follow-up. The mean follow-up time was (39.8±10.5) months. The positive expression of STING were shown in 77 cases (36.7%, 77/210). Recurrence and metastasis occurred in 142 patients. Univariate analysis showed that larger tumors, higher staging (T stage, N stage and TNM stage) and positive STING expression increased the risk of recurrence in patients with gastric cancer treated by surgery [HR (95%CI):1.93 (1.42~2.84), 3.95 (2.61~5.84), 3.25 (2.17~4.86), 4.91 (3.63~7.52), 2.15 (1.33~3.53)]. Compared to patients with negative STING expression, Cox regression analysis showed that patients with positive STING expression had an increased risk of gastric cancer recurrence [HR: 1.98, 95% confidence interval (CI): 1.23~3.32].【Conclusion】 STING is proposed as a novel independent prognostic factor for gastric cancer. Patients with positive expression of STING have a higher risk of postoperative recurrence.
邓峰, 龚晓伟, 杨静. 干扰素基因刺激蛋白在胃癌组织中的表达及其与患者预后的相关性[J]. 医学临床研究, 2020, 37(1): 98-101.
DENG Feng, GONG Xiao-wei, YANG Jing. Correlation between Expression of Stimulator of Interferon Genes and Prognosis in Gastric Cancer Patients with Radical Resection. JOURNAL OF CLINICAL RESEARCH, 2020, 37(1): 98-101.
[1] Brenkman H J, Haverkamp L, Ruurda J P, et al. Worldwide practice in gastric cancer surgery[J]. World J Gastroenterol, 2016,22(15):4041-4048. [2] Liu X, Wang C. The emerging roles of the STING adaptor protein in immunity and diseases[J]. Immunology,2016,147(3):285-291. [3] Ho S S, Zhang W Y, Tan N Y, et al. The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells[J]. Immunity,2016,44(5):1177-1189. [4] Xia T, Konno H, Ahn J, et al. Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates with Tumorigenesis[J]. Cell Rep,2016,14(2):282-297. [5] Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer[J]. Tumour Biol,2017,39(7):1393375038. [6] Dansako H, Ueda Y, Okumura N, et al. The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly[J]. FEBS J,2016,283(1):144-156. [7] Guo H, Konig R, Deng M, et al. NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses[J]. Cell Host Microbe,2016,19(4):515-528. [8] Song S, Peng P, Tang Z, et al. Decreased expression of STING predicts poor prognosis in patients with gastric cancer[J]. Sci Rep,2017,7:39858. [9] Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes[J]. Onco Targets Ther,2016,9:5023-5039.
2020, Vol. 37 
